Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing thera
(Financial Post, 2025-12-03T13:33:34Z)